Medicovestor, Inc., a biotechnology company advancing next-generation antibody-drug conjugates (ADCs), announced that the U.S. Food and Drug Administrati...
AI meets genomics in BioAro’s latest launch, unlocking faster, scalable drug discovery.PanOmiQ™ Research sets a new global benchmark for prec...
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic D...
Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existi...
EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advan...
Yoneda Labs, a leader in computational tools for reaction optimization, has successfully collaborated with Symeres, a leading transatlantic, small molecule...
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an ...
ByteBrain LLC, an emerging AI research and consulting firm, has announced the launch of MEDRAIL, an intelligent platform designed to help pharmaceutical co...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifescienc...
Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, toda...
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on devel...
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to captu...
BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by t...
The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kin...
© 2025 Biopharma Boardroom. All Rights Reserved.
